About the company
Hopstem Biotechnology Co., Ltd. was founded in January 2017, by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem holds world-leading expertise in neural differentiation, cell banking and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). The major aims of our company are to apply these cutting-edge technologies to promote biomedical research, diagnoses and therapies of neurological and other disorders.
Our products/services include different types of high quality human neural cells (HopCellTM neural cells), 2D and 3D models of human nervous system diseases (HopCellTM disease model), neural stem cell culture, differentiation and maturation reagents (HopCellTM reagents), cell line establishing services (HopCellTM cell line services). We also provide services (HopstemTM discovery) on biomarker and drug discovery, including drug screening and neurotoxicity testing, as well as clinical trials of neural progenitor cell transplantation in ischemic stroke and brain injury.